Clinical trials
Phase 2 Carcinoma, Renal Cell trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
33 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2008 | 6 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 19 |
| Terminated | 7 |
| Active, not recruiting | 2 |
| Recruiting | 2 |
| Unknown status | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 5 |
| Novartis Pharmaceuticals | 4 |
| Bayer | 3 |
| Hoffmann-La Roche | 3 |
| Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2 |
| Merck Sharp & Dohme LLC | 2 |
| AIO-Studien-gGmbH | 1 |
| AVEO Pharmaceuticals, Inc. | 1 |
| Bristol-Myers Squibb | 1 |
| Calithera Biosciences, Inc | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Renal Cell | 33 |
| Neoplasm Metastasis | 5 |
| Kidney Neoplasms | 4 |
| Melanoma | 4 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Adenocarcinoma | 2 |
| Carcinoma | 2 |
| Colorectal Neoplasms | 2 |
| Head and Neck Neoplasms | 2 |
| Pancreatic Neoplasms | 2 |
Trials
Showing 1 to 25 of 33. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.